Company profile: Enyo Pharma
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies and discovery solutions, including Vonafexor (EYP001), a synthetic non-steroidal NR1H4 (FXR) agonist in Phase 2 for Alport syndrome, CKD, and NASH; EYP002, a first-in-class chemical series targeting mitochondrial NEET proteins; and a unique drug discovery platform based on biomimetism inspired by viruses.
Products and services
- Vonafexor (EYP001): A clinical-stage synthetic non-steroidal agonist of NR1H4 (farnesoid X receptor) exhibiting fibrolytic and anti-inflammatory activity, in Phase 2 for Alport syndrome, CKD, and NASH
- Drug Discovery Platform: A biomimetic platform inspired by viruses that leverages virus-host protein interaction expertise to architect therapeutics, developed by experts in virus-host interactions and pharmaceutical industry executives
- EYP002: A first-in-class chemical series in lead optimization targeting mitochondrial NEET proteins, initially developed using a phenotypic assay based on inhibition of influenza replication
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enyo Pharma
Cinclus Pharma
HQ: Sweden
Website
- Description: Provider of research-based biotech solutions developing small-molecule therapies for gastric acid–related diseases, notably linaprazan glurate for GERD and Helicobacter pylori with improved action over PPIs. Completed Phase II and preparing Phase III for GERD; QIDP designation from the FDA for H. pylori. Based in Basel, Switzerland; main asset X842 studied in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinclus Pharma company profile →
ARYx Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical solutions focused on retrometabolic drug design to improve the safety of oral therapies for chronic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ARYx Therapeutics company profile →
Norgine
HQ: The Netherlands
Website
- Description: Provider of specialist pharmaceuticals with direct commercial presence in major European markets and infrastructure to develop, manufacture and commercialise therapies, including MOVICOL for chronic constipation; MOVIPREP and PLENVU for colon cleansing before colonoscopy; XIFAXAN for hepatic encephalopathy; FERACCRU for iron deficiency anemia; and LYMPHOSEEK for lymphatic mapping and sentinel lymph node biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Norgine company profile →
Protagonist Therapeutics
HQ: Australia
Website
- Description: Provider of orally-stable peptide therapeutics to treat diseases currently addressed by injectable antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protagonist Therapeutics company profile →
Invendo Medical
HQ: Germany
Website
- Description: Provider of single-use, robotically-assisted endoscopy technology and disposable, highly flexible, easy-to-use endoscopy products in gastroenterology, aimed at eliminating gastrointestinal endoscopy challenges.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Invendo Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enyo Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enyo Pharma
2.2 - Growth funds investing in similar companies to Enyo Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enyo Pharma
4.2 - Public trading comparable groups for Enyo Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →